Sign inJoin waitlistJoin the waitlist

AC

Andy Chen

Associate Professor of Medicine, Division of Hematology/Medical Oncology, School of Medicine · Oregon Health & Science University

Credentials: · · · · · ·

History

Oregon Health & Science University
Present

Research

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a…
The Lancet · 2015 · 573 citations
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
Nature Medicine · 2022 · 478 citations
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)
The Lancet Haematology · 2019 · 212 citations

Richard Maziarz
15 papers
Veronika Bachanova
10 papers
Hillard Lazarus
8 papers
CF
Cesar Freytes
7 papers
Sonali Smith
7 papers
DI
David Inwards
6 papers
Mohamed Dabaja
6 papers
Peter Riedell
6 papers
Stephen Schuster
6 papers
TF
Timothy Fenske
6 papers
BS
Bipin Savani
5 papers
CO
Craig Okada
5 papers